Floatz logo

Cdca1

Metastatic Breast Cancer

Tokyo Medical UniversityvaccinePhase 1Dormant
CC
42/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
73/ 100

Competitive context

62 Active assets in the Metastatic Breast Cancer cohort.

Asset / SponsorPhaseRating
Trastuzumab Duocarmazine
Byondis B.V.
Phase 3BB
Capivasertib
Maryam Lustberg
Phase 3BB
Alisertib
Puma Biotechnology, Inc.
Phase 2BB
Bp-C1
Meabco A/S
Phase 2BB
Encequidar
Health Hope Pharma
Phase 3B

View all 50 →

Same molecule, other indications

Cdca1 is also rated in:

Non Small Cell Lung CancerDormant
CCC
Indicative ·
53 / 100
View asset →
small cell lung carcinomaDormant
CC
Indicative ·
40 / 100
View asset →
prostate cancerDormant
CC
Indicative ·
40 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →